ABSTRACT
Background: Finasteride and dutasteride are inhibitors of the enzyme 5-alpha-reductase which inhibits the conversion of testosterone to dihydrotestosterone. Dutasteride inhibits both type I and type II 5-alpha-reductase while fi nasteride inhibits only the type II enzyme. As both isoenzymes are present in hair follicles, it is likely that dutasteride is more effective than fi nasteride. Aims: To compare the effi cacy, safety and tolerability of dutasteride and fi nasteride in men with androgenetic alopecia. Methods: Men with androgenetic alopecia between 18 and 40 years of age were randomized to receive 0.5 mg dutasteride or 1 mg fi nasteride daily for 24 weeks. The primary effi cacy variables were hair counts (thick and thin) in the target area from modifi ed phototrichograms and global photography evaluation by blinded and non-blinded investigators. The secondary effi cacy variable was subjective assessment using a preset questionnaire. Patients were assessed monthly for side effects. Results: Ninety men with androgenetic alopecia were recruited. The increase in total hair count per cm2 representing new growth was signifi cantly higher in dutasteride group (baseline- 223 hair; at 24 weeks- 246 hair) compared to fi nasteride group (baseline- 227 hair; at 24 weeks- 231 hair). The decrease in thin hair count per cm2 suggestive of reversal of miniaturization was signifi cantly higher in dutasteride group (baseline- 65 hair; at 24 weeks- 57 hair) compared to fi nasteride group (baseline- 67 hair; at 24 weeks- 66 hair). Both the groups showed a similar side effect profi le with sexual dysfunction being the most common and reversible side effect. Limitations: Limitations include the short duration of the study (6 months), the small sample size and the fact that it was an open-label study. Conclusions: Dutasteride was shown to be more effi cacious than fi nasteride and the side-effect profi les were comparable.
ABSTRACT
BACKGROUND: To date, numerous studies have investigated the epidemiology and clinical characteristics of male pattern hair loss (MPHL). OBJECTIVE: The purpose of this study was to evaluate a large number of long-term MPHL patients and to compare them to shorter term ones from other studies. METHODS: We retrospectively reviewed charts of patients diagnosed with MPHL during a 10-year period at the alopecia clinic at the Department of Dermatology of Myongji Hospital. RESULTS: Among 3,549 alopecia patients who had visited the hospital's alopecia clinic, 1,360 were patients demonstrating MPHL (38.3%). The most frequent age group was patients in their 20's (30.1%) followed by those in their 30's (28.2%), 40's (17.2%), 50's (9.9%), and teenagers (8.9%). There were 599 MPHL patients (44.0%) with a paternal familial predisposition, 182 (13.4%) with a maternal familial predisposition, and 118 (8.7%) with familial predisposition on maternal and paternal sides. MPHL was classified based on the Norwood-Hamilton classification: type 2 (20.0%), type 3v (19.4%), and type 3a (16.3%) were the most frequent. Abnormalities in total serum cholesterol were found in 15.1% patients and triglycerides in 36.1% of patients. The most common comorbidity was seborrheic dermatitis, followed by hypertension, hyperlipidemia, diabetes mellitus, and gastrointestinal diseases. CONCLUSION: This study demonstrated that the period of MPHL diagnosis and treatment becomes earlier in age and milder regarding MPHL type, which may be due to early puberty in teenagers.